Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Organic Chemicals
Amines
Clear Filters

Search Clinical Trials

12 Results
Active, Not Recruiting
Post IVIG Medication in Children With Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is the most common acquired immune cytopenia in childhood, affecting 4-6 in 100,000 children. The pathophysiology of ITP is highly complex and incompletely understood. Accepted mechanisms include …
Baylor Role: Lead Sponsor
Completed
DOX as a Potential Treatment for Methamphetamine Dependence
Purpose: To determine the effects of treatment with doxazosin, compared to treatment with placebo, on methamphetamine-induced craving and subjective effects in methamphetamine-dependent human volunteers. Secondary aims are to clarify the …
Baylor Role: Lead Sponsor
Completed
Varenicline as a Treatment for Methamphetamine Dependence
This study is part of an effort to develop treatments for methamphetamine abuse. Varenicline is a drug that changes levels of certain brain chemicals that may also be useful in …
Baylor Role: Lead Sponsor
Completed
NAC as a Potential Treatment for Methamphetamine Dependence
N-acetyl-l-cysteine (NAC) treatment is associated with reduced susceptibility to reinstatement of cocaine seeking behavior in rats (Baker et al 2002) and with reduced cue-induced craving in cocaine-dependent human volunteers (LaRowe …
Baylor Role: Lead Sponsor
Withdrawn
RTI-336 as a Treatment for Methamphetamine Dependence
Methamphetamine (METH) is a highly addictive stimulant and acute exposure causes dopamine (DA) release and stimulates midbrain reward centers. The proposed work represents an important research effort with considerable public …
Baylor Role: Lead Sponsor
Completed
Rivastigmine as a Treatment for Methamphetamine Dependence
We recently completed a double-blind placebo-controlled human laboratory study demonstrating that treatment with a low dose of the acetylcholinesterase (AChE) inhibitor rivastigmine reduced methamphetamine (METH)-induced craving (see Preliminary Studies, Fig. …
Baylor Role: Lead Sponsor
Completed
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
Our preliminary data indicate that the ACE inhibitor perindopril can attenuate MA-induced drug craving, suggesting that perindopril should be evaluated as a treatment for MA dependence. Candesartan works similarly to …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
The donor gave us blood to make CD19 chimeric receptor trivirus specific T cells in the laboratory. These cells were grown and frozen for the subject. To make these special …
Baylor Role: Lead Sponsor
Withdrawn
Varenicline-Methamphetamine Interaction Study (2008)
See Brief Summary
Baylor Role: Lead Sponsor
Completed
Selegiline to Zelapar Switch Study in Parkinson Disease Patients
This is an open label, multicenter, 6 week study of the conversion from oral selegiline to orally disintegrating selegiline in PD patients with or without motor fluctuations, and currently taking …
Baylor Role: Lead Sponsor